title: New avenues for targeted therapies and biomarkers in anaplastic large cell lymphoma.
authors.affiliation: Clinical Institute of Pathology, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria.|Ludwig Boltzmann Institute Applied Diagnostics, Währinger Gürtel 18-20, 1090 Vienna, Austria.
authors.forename: Gerda
authors.initials: G
authors.lastname: Egger
authors.affiliation: Division of Molecular Histopathology, Department of Pathology, University of Cambridge, Lab Block Level 3, Addenbrooke's Hospital, Cambridge CB20QQ, UK.
authors.forename: Suzanne D
authors.initials: SD
authors.lastname: Turner
mesh_terms: D000077548:Anaplastic Lymphoma Kinase; D014408:Biomarkers, Tumor; D019175:DNA Methylation / Q000235:genetics; D044127:Epigenesis, Genetic / Q000187:drug effects; D006801:Humans; D017728:Lymphoma, Large-Cell, Anaplastic / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics* / Q000378:metabolism; D058990:Molecular Targeted Therapy; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000235:genetics
chemical_list: D014408:Biomarkers, Tumor; D047428:Protein Kinase Inhibitors; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D020794:Receptor Protein-Tyrosine Kinases
keywords: DNA methylation; NPM-ALK; anaplastic large cell lymphoma; crizotinib